Shailender Bhatia

机构：Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa, University of Washington, Fred Hutch Cancer Center · ORCID：0000-0002-3816-2238

发表论文 335 篇 · 总被引 27998 次 · h-index 58

代表论文

• NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024 (2024 · Journal of the National Comprehensive Cancer Network · 被引 158)
• A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer (2025 · ESMO Open · 被引 80)
• Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications (2024 · Journal of Clinical Oncology · 被引 32)
• Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study (2025 · Journal of Clinical Oncology · 被引 22)
• Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report (2025 · European Heart Journal - Case Reports · 被引 19)
• Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors (2025 · Journal for ImmunoTherapy of Cancer · 被引 13)